Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31

Oncogene volume 18, pages 157–163 (1999)Cite this article

Abstract

The most common genetic alteration identified in transitional cell carcinoma (TCC) of the bladder is loss of heterozygosity (LOH) on chromosome 9. However, localization of tumor suppressor genes on 9q has been hampered by the low frequency of subchromosomal deletions. We have analysed 139 primary, initial low stage TCC of the bladder using a panel of 28 microsatellite markers spanning chromosome 9 at an average distance of 5 Mb, following a primer-extension preamplification (PEP) technique. Sixty-seven (48%) tumors showed LOH at one or more loci and partial deletions were detected in 62 (45%) tumors; apparent monosomy 9 was detected in only five (4%) tumors. Deletions were more frequent on 9q (44%) than on 9p (23%), the latter being mostly associated with 9q deletion, suggesting that alteration of genes on 9q may be an early event associated with superficial papillary tumors. Combined data from the cases with partial 9q deletions displayed four candidate regions for tumor suppressor loci, based on the frequency of deletion observed and tumors with unique deletions at these sites. In two tumors, the unique partial deletion comprised D9S12 at 9q22.3, a region encompassing loci for the Gorlin syndrome and multiple self-healing squamous epithelioma gene. In two other tumors, the single LOH was identified at the D9S172 locus at 9q31-32 where the dysautonia and Fukuyama-type congenital muscular dystrophy genes have been located. One tumor showed unique LOH at the GSN locus at 9q33, a region frequently deleted in other sporadic tumors while the fourth region of deletion was observed at 9q34 between ASS and ABL-1, in two tumors. This region is frequently deleted in tumors and encompasses the locus for the hereditary hemorrhagic telangiectasia gene. These findings suggest four target regions on 9q within which suppressor genes for TCC may reside.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Allard P, Fradet Y, Têtu B, Bernard P and the Québec Urology Research Group. . 1995 Clin. Cancer Res. 1: 1195–1202.

  • Cairns P, Shaw ME and Knowles MA. . 1993 Cancer Res. 53: 1230–1232.

  • Cairns P, Tokino K, Eby Y and Sidransky D. . 1994 Cancer Res. 54: 1422–1424.

  • Dalbagni G, Presti J, Reuter V, Fair WR and Cordon-Cardo C. . 1993 Lancet 342: 469–471.

  • Devlin J, Keen AJ and Knowles MA. . 1994 Oncogene 9: 2757–2760.

  • Diaz MO, Rubin CM, Harden A, Ziemen S, Larson RA, Le Beau MM and Rowley JD. . 1990 N. Engl. J. Med. 322: 77–82.

  • Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE and Dracopoli NC. . 1992 Proc. Natl. Acad. Sci. USA 89: 10557–10561.

  • Habuchi T, Devlin J, Elder PA and Knowles MA. . 1995 Oncogene 11: 1671–1674.

  • Habuchi T, Yoshida O and Knowles MA. . 1997 Hum. Mol. Genet. 6: 913–919.

  • Hornigold N, Van Slegtenhorst M, Nahmias J, Ekong R, Rousseaux S, Hermans C, Halley D, Povey S and Wolfe JA. . 1997 Genomics 41: 385–389.

    Article  CAS  Google Scholar 

  • Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RSl, Johnson BE and Skolnick MH. . 1994 Science 264: 436–440.

    Article  CAS  Google Scholar 

  • Keen AJ and Knowles MA. . 1994 Oncogene 9: 2083–2088.

  • Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law MG. . 1994 Cancer Res. 54: 531–538.

  • LaRue H, Simoneau M and Fradet Y. . 1995 Clinical Cancer Res. 1: 435–440.

  • Linnenbach AJ, Pressler LB, Seng BA, Kimmel BS, Tomaszewski JE and Malkowicz SB. . 1993 Hum. Mol. Genet. 2: 1407–1411.

  • Marchuk DA, Papenberg KA, Jackson CE, Markel DS, Guttmacher AE and Greenspan DS. . 1994 Ann. Hum. Genet. 58: 224–225.

  • McDonald MT, Papenberg KA, Ghosh S, Glatfelter AA, Biesecker BB, Helmbold EA, Markel DS, Zolotor A, McKinnon WC, Vanderstoep JL, Jackson CE, Iannuzzi M, Collins FS, Boehnke M, Porteous ME, Guttmacher AE and Marchuk DA. . 1994 Nature Genet. 6: 197–204.

  • Meldgaard P, Johnson PH, Langkilde NC, Wolf H and Orntoft TF. . 1995 Int. J. Cancer 63: 341–344.

    Article  CAS  Google Scholar 

  • Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB and Sidransky D. . 1994 Cancer Res. 54: 2322–2326.

  • Miyake M, Nakahori Y, Matsushita I, Kobayashi K, Mizuno K, Hirai M, Kanazawa I, Nakagome Y, Tokunaga K and Toda T. . 1997 Genomics 40: 284–293.

    Article  CAS  Google Scholar 

  • Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH, Gonzalezzulueta M, Nichols PW, Skinner DG and Jones PA. . 1993 Cancer Res. 53: 4066–4070.

  • Nobori T, Miura K, Lois A, Takabayashi K and Carson DA. . 1994 Nature 368: 753–756.

    Article  CAS  Google Scholar 

  • Northrup H, Greenspan DS, Au KS and Blanton SH. . 1994 Ann. Hum. Genet. 58: 229–230.

  • Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, Nobori T, Cowan JM, Rowley JD and Diaz MO. . 1992 Cancer Res. 52: 2523–2529.

  • Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE and Cordon-Cardo C. . 1994 Cancer Res. 54: 2848–2851.

  • Ozelius LJ, Hewett J, Kramer P, Bressman SB, Shalish C, De Leon D, Rutter M, Risch N, Brin MF, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, McCormick MK, Fahn S, Buckler AJ, Gusella JF and Breakefield XO. . 1997 Genome Res. 7: 483–494.

    Article  CAS  Google Scholar 

  • Pericak-Vance MA, Bale AE, Haines JL, Kwiatkowski DJ, Pilz A, Slaugenhaupt S, White JA, Edwards JH, Marchuk D, Olopade OI, Attwood J and Povey S. . 1995 Ann. Hum. Genet. 59: 347–365.

  • Povey S, Smith M, Haines J, Kwiatkowski D, Fountain J, Bale A, Abbott C, Jackson I, Lawrie M and Hulten M. . 1992 Ann. Hum. Genet. 56: 167–182.

  • Povey S, Armour J, Farndon P, Haines JL, Knowles M, Olopade F, Pilz A and White JA. . 1994 Ann. Hum. Genet. 58: 177–200.

  • Povey S, Attwood J, Chadwick B, Frezal J, Haines JL, Knowles M, Kwiatkowski DJ, Olopade OI, Slaugenhaupt S, Spurr NK, Smith M, Steel K, White JA and Pericak-Vance MA. . 1997 Ann. Hum. Genet. 61: 183–206.

    CAS  PubMed  Google Scholar 

  • Rousseau F, Réhel R, Rouillard P, DeGranpré P and Khandjian EW. . 1994 Human Mutation 4: 51–54.

    Article  CAS  Google Scholar 

  • Ruppert JM, Tokino K and Sidransky D. . 1993 Cancer Res. 53: 5093–5095.

  • Shapiro GI and Rollins BJ. . 1996 Biochim. Biophys. Acta. 1242: 165–169.

  • Simoneau AR, Spruck CH III, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T and Jones PA. . 1996 Cancer Res. 56: 5039–5043.

  • Stadler WM, Sherman J, Bohlander SK, Roulston D, Dreyling M, Rukstalis D and Olopade OI. . 1994 Cancer Res. 54: 2060–2063.

  • Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara N, Koyanagi T and Kuzumaki N. . 1995 Cancer Res. 55: 3228–3232.

  • Van Slegtenhorst M, De Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, Van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M and Ravine D. . 1997 Science 277: 805–808.

  • Van Tilborg AAG, Hekman ACP, Vissers KJ, van der Kwast TH and Zwarthoff EC. . 1998 Int. J. Cancer 75: 9–14.

    Article  CAS  Google Scholar 

  • Zhang L, Cui X, Schmitt K, Hubert R, Navidi W and Arnheim N. . 1992 Proc. Natl. Acad. Sci. USA 89: 5847–5851.

Download references

Acknowledgements

This work was supported by the National Cancer Institute of USA, grant #CA47526. FR is a MRC scientist.

Author information

Authors and Affiliations

  1. Laboratoire d'Uro-Oncologie Expérimentale, Centre de recherche en cancérologie du Pavillon Hôtel-Dieu de Québec, Québec, Canada

    Maryse Simoneau, Tahar O Aboulkassim, Hélène LaRue & Yves Fradet

  2. Unité de recherche en génétique humaine et moléculaire, Pavillon St-François d'Assise, Centre Hospitalier Universitaire de Québec, Québec, Canada

    François Rousseau

Authors
  1. Maryse Simoneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tahar O Aboulkassim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hélène LaRue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. François Rousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yves Fradet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simoneau, M., Aboulkassim, T., LaRue, H. et al. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 18, 157–163 (1999). https://doi.org/10.1038/sj.onc.1202277

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202277

Keywords

This article is cited by

Search

Advanced search

Quick links